Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Mucosal Melanoma: early-phase trial registry
2 of 13 indexed Mucosal Melanoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,315 of 28,707 conditions by registered trial count.
13 US clinical trials · 2 currently recruiting · #1,315 of 28,707 conditions by registered trial count
Mucosal Melanoma: 13 US clinical trials tracked, 2 recruiting.
Mucosal Melanoma is the subject of 13 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 5 of these trials.
Enrollment posture brief
Registry condition mucosal-melanoma
OPEN 2 | RECR 15% | LATE 1 | EARLY 12 | RANK #1315 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Arthroplasty, Replacement, Knee (15% recruiting · 13 trials)
Mucosal Melanoma lists 2 open slots (15% of 13 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Mucosal Melanoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Mucosal Melanoma is recruiting below its size-band peers.
2 of 13 indexed trials (15.4%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Mucosal Melanoma research.
National Cancer Institute (NCI) accounts for 5 of 13 trials (38.5%). 9 distinct sponsors appear on at least one study for this condition label.
-
Most Mucosal Melanoma trials plan to enrol fewer than 100 people.
Median target enrolment is 50 among the 13 trials that report a genuine target (sentinel values excluded). 9 of those (69.2%) plan for fewer than 100 participants.
-
Mucosal Melanoma research is mostly interventional.
13 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
13 total, page 1 of 1
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
National Cancer Institute (NCI)
NCT05111574
Axitinib and Nivolumab for the Treatment of Mucosal Melanoma
Memorial Sloan Kettering Cancer Center
NCT05384496
A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma
National Cancer Institute (NCI)
NCT03698019
A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
Ascentage Pharma Group
NCT03611868
Dinaciclib in Treating Patients With Stage IV Melanoma
National Cancer Institute (NCI)
NCT00937937
Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy
M.D. Anderson Cancer Center
NCT04645680
Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma
Robert R. McWilliams, MD
NCT03241186
Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
H. Lee Moffitt Cancer Center and Research Institute
NCT05628883
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT00110019
Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma
National Cancer Institute (NCI)
NCT03033576
Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists
Craig L Slingluff, Jr
NCT02126579
Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma
Dana-Farber Cancer Institute
NCT00424515
A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas
Hoffmann-La Roche
NCT04551352
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 8 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Mucosal Melanoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Mucosal Melanoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Mucosal Melanoma page
13 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Mucosal Melanoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Mucosal Melanoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Mucosal Melanoma condition card totals 13 registered trials; most-linked intervention Computed Tomography; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.